Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains the results of the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.
SOPHIA Trial in HER+ Metastatic Breast Cancer
